Zosano Pharma (ZSAN) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update
November 9, 2017 4:05 PM ESTFirst patient enrolled in long term safety study in November 2017Phase 2/3 data presented at International Headache Society in SeptemberClinical results published in two leading scientific journalsAccess to capital expanded to fund Long-term Safety Study
FREMONT, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ: ZSAN) a clinical stage biopharmaceutical company focused on providing systemic administration of therapeutics to patients using our proprietary Adhesive Dermally-Applied Microarray (ADAM) technology, today announced financial results for the third quarter ended September 30, 2017.
We continue our... More
